Document Detail


Individual predictors of increased serum mesothelin in asbestos-exposed workers.
MedLine Citation:
PMID:  23277285     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The soluble mesothelin-related peptide (SMRP), a candidate marker for screening of subjects with asbestos exposure, is influenced by some individual and clinical factors. The aim of this study was to quantify the role of age, smoking, weight, presence of diseases and exposure to asbestos on serum SMRP levels in a large series of subjects exposed to asbestos, possible candidates for mesothelioma screening. One thousand seven hundred and four participants underwent clinical examination and were interviewed on medical anamnesis, occupation, smoking and weight. SMRP was measured by an ELISA assay. Overall, median SMRP was 0.4 (IQR 25-75: 0.3-0.7) nmol/l. It was higher in current smokers and in subjects with a cumulative asbestos exposure >50 ff/cc/years than in all the other subjects (p < 0.001 and p = 0.002, respectively). SMRP was positively correlated with age (ρ = 0.11, p < 0.001) and, inversely, with BMI (ρ = -0.15, p < 0.001). SMRP was lower in healthy subjects (n = 1,217: median 0.4 nmol/l) than in subjects with malignant tumors (n = 118: 0.5 nmol/l; p = 0.01), asbestos-related pleural lesions (plaques or thickenings, n = 152: 0.6 nmol/l; p < 0.001) and other benign diseases (n = 182: 0.5 nmol/l; p = 0.04). Multivariate analysis revealed significant predictors of increased SMRP: age >57 years, current smoking, a positive anamnesis for cancer and for asbestos-related pleural lesions, and BMI < 25. Some clinical and demographic variables are associated with serum SMRP levels. The degree of these associations is low, nevertheless they should be accounted for in the interpretation of SMPR as a candidate marker predictive of mesothelioma. The potential predictive value of serum SMRP in screening/surveillance programs must be validated in prospective studies.
Authors:
Rosa Filiberti; Paola Marroni; Manlio Mencoboni; Virginia Mortara; Pietro Caruso; Alex Cioè; Luigi Michelazzi; Domenico F Merlo; Andrea Bruzzone; Barbara Bobbio; Lisette Del Corso; Roberto Galli; Paola Taveggia; Guglielmo Dini; Fabio Spigno
Related Documents :
24206165 - A receptor-based bioadsorbent to target advanced glycation end products in chronic kidn...
20604775 - Age-specific patterns of unsatisfactory results for conventional pap smears and liquid-...
20660435 - Flexible sigmoidoscopy screening for colorectal cancer: uptake in a population-based pi...
6452525 - Maternal age and origin of non-disjunction in trisomy 21.
1389605 - Undergraduate teaching in geriatric dentistry.
16002215 - Uncertainty, anxiety, and brain oscillations.
Publication Detail:
Type:  Journal Article     Date:  2013-01-01
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  422     Citation Subset:  IM    
Affiliation:
Epidemiology, Biostatistics and Clinical Trials, IRCCS AOU San Martino-IST - Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132, Genoa, Italy, rosangela.filiberti@istge.it.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal ca...
Next Document:  Enhancement of cisplatin-induced apoptosis by ?-elemene in resistant human ovarian cancer cells.